ADC Therapeutics SA has described antibody-drug conjugates comprising antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) covalently linked to exatecan through a linker reported to be useful for the treatment of ovarian cancer and non-small-cell lung cancer (NSCLC).

Gen1e Lifesciences Inc. has disclosed drugs targeting extracellular-regulated kinase (ERK) reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune and lung diseases.

Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has discovered compounds acting as diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.

Suzhou Zion Pharma Technology Co. Ltd. has described transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) and/or probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer and viral infections.

Shanghai Ennova Biopharmaceutical Co. Ltd. has identified condensed ring compounds acting as ATP-dependent 6-phosphofructokinase, liver type (PFKL) activators reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, lung diseases, metabolic diseases, sepsis and thrombosis.

ADC Therapeutics SA has synthesized antibody-drug conjugates comprising antibody targeting neutral amino acid transporter B(0) (SLC1A5; ASCT2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer.

Pillai Universal LLC has disclosed compounds reported to be useful for the treatment of metastatic cancer.

Gen1e Lifesciences Inc. and the University of Maryland have patented mitogen-activated protein kinase 1 (MAPK1; ERK2) and/or mitogen-activated protein kinase 3 (MAPK3; ERK1) inhibitors.

Shanghai Xianxiang Medical Technology Co. Ltd. has identified diacylglycerol kinase inhibitors reported to be useful for the treatment of cancer.

Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via linkers acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.